Search PubMed⌕ Search

Biomedical subjects

L C Parish

Publications and source records attributed to L C Parish.

At least 91 records · Page 5Linked to original sources
PubMed1986

Cephalosporins in cutaneous infections. A prospective comparison of two dosage regimens of ceftazidime for therapy of skin and skin structure infections.

The safety and efficacy of ceftazidime administered as 0.5 g every 8 hours (q8h) or 1.0 g q8h for at least 5 days were compared in 197 patients and found to be effective in the treatment of cellulitis, abscesses, skin ulcers, and wound infections. Staphylococcus aureus was the predominant pathogen in both treatment groups with approximately half of the isolates from each treatment group being gram-positive. Pseudomonas aeruginosa was the most common gram-negative isolate. P. aeruginosa, Proteus mirabilis, and Escherichia coli each comprised 5-12% of the isolates from each treatment group. Clinical cure or improvement was achieved in 98.7% of the patients in each treatment group. Concurrently with clinically successful treatment, a high rate of bacteriologic eradication without superinfection was achieved with the 0.5-g regimen (84% of all isolates) and the 1.0-g regimen (92%).

Adolescent↗
PubMed1985

Alcoholism and skin disease.

One hundred and one patients who met criteria for alcoholism were evaluated for dermatologic signs. There were 98 men and 3 women, with an average age of 40.85 years; 40 were white and 61 black. Significant findings were no skin disease in 19, acne in 27, folliculitis in 8, seborrheic dermatitis in 12, tinea pedis in 32, and xerosis in 7. Only two patients had rosacea, which is contrary to previously held beliefs about the drinker's nose.

Acne Vulgaris↗
PubMed1985

Candidiasis: the isomorphic response.

Two uncontrolled insulin dependent diabetic patients had Candida albicans infection with the unique manifestation of erythematous scaling papulopustules at the sites of excoriation. In one patient, the clinical presentation suggested herpes zoster. Recognition of this picture and the contributing factors, i.e. Candida infected finger nails and elevated blood sugar will permit early use of appropriate antifungal therapy.

Aged↗
PubMed1984

Ceftizoxime treatment of cutaneous and subcutaneous tissue infections.

Forty-seven adults with infected cutaneous lesions including decubitus ulcers, leg ulcers, cellulitis, pyoderma, and infected dermatitis were treated in a randomized single-blind study with ceftizoxime (2 gm/day, administered intravenously) or cefamandole (4 gm/day, administered intravenously). The duration of treatment ranged from five to 17 days with ceftizoxime and from six to 14 days with cefamandole. Both gram-positive cocci (mostly Staphylococcus sp) and gram-negative bacilli were cultured from the infected areas before treatment. Clinical and bacteriological responses to both drugs were excellent. Ceftizoxime at a dosage of 1 gm twice daily proved to be at least as effective as 1 gm of cefamandole given four times daily. Both drugs were well tolerated, effective, and safe in the treatment of skin and skin-structure infections. Neither drug therapy had to be discontinued because of adverse effects.

Adult↗
PubMed1984

Ceforanide compared with cefazolin in skin and soft tissue infections.

The response of serious skin and skin structure infections to ceforanide 1 gm every twelve hours or cefazolin 1 gm every eight hours was evaluated in ninety-six patients hospitalized for treatment. Most of the patients had decubitus ulcers; predominant pathogens were Staphylococcus aureus, Escherichia coli, and Proteus mirabilis. Ceforanide produced a satisfactory clinical response in 89 percent (forty-eight of fifty-four) of the patients evaluated and eradicated 90 percent (seventy-four of eighty-two) of the pathogens. Although the clinical response of forty-two cefazolin-treated patients was similar (satisfactory response in 86 percent, thirty-six patients), only 81 percent (forty-eight of fifty-nine) of the pathogens were eradicated. Both ceforanide and cefazolin were very well tolerated systemically and locally.

Adult↗
PubMed1984

Treatment of skin and skin structure infections: a comparative study of Augmentin and cefaclor.

Sixty-four patients were entered into a double-blind study of Augmentin and cefaclor. Pathogenic bacteria were recovered from twenty-one patients who received Augmentin and seventeen patients who received cefaclor. The primary diagnoses were pyodermas and impetigo, as well as cellulitis, folliculitis, infected skin structure, and infected surgical sites. Eighty-one percent of the Augmentin-treated patients were classified as successfully treated, based on clinical and bacteriologic criteria, as were eighty-nine percent of the patients treated with cefaclor. Side effects were minimal in both groups; no laboratory abnormalities were found. Both Augmentin and cefaclor are useful oral antimicrobial agents in the treatment of infections of the skin and skin structure.

Adult↗